α-Santalol/Sandalwood oil / Bcl-2 Cancer Research Results

SAO, α-Santalol/Sandalwood oil: Click to Expand ⟱
Features:

α-Santalol / Sandalwood oil — α-Santalol is a lipophilic sesquiterpene alcohol and major bioactive constituent of East Indian sandalwood oil from Santalum album. It is best classified as a natural-product small molecule / essential-oil sesquiterpenoid, with sandalwood oil functioning as a botanical mixture source rather than a single-compound drug. Standard abbreviations include α-SAN, alpha-santalol, and SAO or EISO for sandalwood album / East Indian sandalwood oil. The oncology evidence is primarily preclinical, strongest for skin, prostate, breast, and oral cancer models, with no established oncology indication.

Primary mechanisms (ranked):

  1. Induction of intrinsic and extrinsic apoptosis through caspase activation, PARP cleavage, mitochondrial involvement, and increased apoptotic signaling.
  2. Cell-cycle blockade, especially G2/M arrest, with reported tubulin interaction and mitotic disruption in oral cancer models.
  3. Suppression of AKT–survivin / IAP survival signaling, including reduced p-AKT, survivin, XIAP, PCNA, cyclin D, and CDC2 in prostate cancer models.
  4. Anti-migration and anti-invasive signaling through Wnt/β-catenin inhibition in breast cancer models.
  5. Anti-angiogenic signaling through VEGFR2–AKT/mTOR/p70S6K pathway suppression in prostate tumor models.
  6. Autophagy modulation, including AKT–mTOR-linked autophagy in prostate cancer and autophagy/cell death effects for whole sandalwood oil in proliferating keratinocytes.
  7. Skin chemopreventive modulation of UVB/chemical carcinogenesis pathways, including p53/caspase-associated apoptosis and inflammatory stress-response modulation.

Bioavailability / PK relevance: α-Santalol is a small, highly lipophilic sesquiterpene alcohol, so topical and transdermal exposure is plausible, but formal human systemic PK data are limited. Oral/transdermal use should be treated as formulation- and dose-dependent, and essential-oil exposure is not equivalent to purified α-santalol exposure.

In-vitro vs systemic exposure relevance: Most anticancer cell-culture studies use micromolar α-santalol concentrations, commonly around 20–75 μM depending on model and endpoint. These levels should be considered potentially above reliably documented human systemic exposure from sandalwood oil use, so in-vitro anticancer potency should not be interpreted as clinically achievable without dedicated PK/formulation data.

Clinical evidence status: Preclinical for cancer prevention/therapy. Small human and dermatology-oriented evidence exists for sandalwood album oil in non-oncology skin conditions, and one clinical-trial context appears related to oral mucositis/supportive care rather than anticancer efficacy. No approved oncology indication and no high-quality human RCT evidence for cancer treatment were identified.

α-Santalol and Sandalwood Oil Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Caspase apoptosis ↑ caspase-3, ↑ caspase-8, ↑ caspase-9, ↑ PARP cleavage, ↓ viability ↔ to modest toxicity at comparable experimental windows (model-dependent) R/G Pro-apoptotic anticancer effect Core mechanism across prostate, breast, and skin cancer models; includes intrinsic and extrinsic apoptotic signaling.
2 Mitochondria / MPTP ↑ mitochondrial apoptotic signaling, ↓ mitochondrial membrane integrity (model-dependent) ↔ uncertain R/G Amplifies apoptosis Mitochondrial involvement is supported mainly through caspase-9 and apoptotic readouts; direct MPTP evidence is not as strong as apoptosis evidence.
3 Cell cycle and tubulin ↑ G2/M arrest, ↓ tubulin polymerization, ↑ mitotic arrest ↔ uncertain G Anti-proliferative cytostasis and cytotoxicity Strong mechanistic relevance for oral cancer and skin/breast cancer models; tubulin interaction supports antimitotic classification.
4 AKT / survivin / IAP ↓ p-AKT, ↓ survivin, ↓ XIAP, ↓ PCNA, ↓ cyclin D, ↓ CDC2 ↔ uncertain G Reduces survival signaling and proliferation Important prostate-cancer axis; PI3K/AKT inhibition can enhance α-santalol-induced apoptosis.
5 Wnt / β-catenin migration ↓ β-catenin-linked migration and motility ↔ uncertain G Anti-migration effect Best supported in cultured breast cancer cells; therapeutic relevance remains preclinical.
6 VEGFR2 angiogenesis ↓ VEGFR2 signaling, ↓ AKT/mTOR/p70S6K, ↓ tumor angiogenesis ↔ uncertain G Anti-angiogenic effect Relevant to prostate tumor xenograft-type evidence; not yet clinically validated.
7 Autophagy / AKT-mTOR ↑ autophagy (context-dependent), ↓ AKT-mTOR signaling ↑ autophagy/cell death in proliferating keratinocytes with whole oil (context-dependent) G Context-dependent stress adaptation or cell death Autophagy may be protective in some prostate cancer contexts; combination strategies would need caution.
8 ROS / oxidative stress ↔ limited direct cancer-specific evidence for α-santalol as a primary ROS driver ↔ antioxidant effects reported in non-cancer models R/G Secondary or context-dependent redox modulation ROS is not a core anticancer mechanism unless a specific model/source directly shows ROS-dependent killing.
9 NRF2 ↔ insufficient direct α-santalol cancer evidence ↔ uncertain G Not a primary assigned mechanism
10 Glycolysis / HIF-1α ↔ insufficient direct evidence ↔ insufficient direct evidence G No clear primary modulation
11 Radiosensitization or chemosensitization ↔ limited direct evidence; possible apoptosis-combination rationale only ↔ uncertain G Unproven adjunct effect
12 Clinical Translation Constraint In-vitro potency may require exposure above documented human systemic levels Topical irritation or sensitization possible; systemic safety data limited G Limits clinical interpretation Major constraints are formulation, bioavailability, mixture variability, topical safety, and lack of oncology trials.

P: 0–30 min R: 30 min–3 hr G: >3 hr
Bcl-2, B-cell CLL/lymphoma 2: Click to Expand ⟱
Source: HalifaxProj (inhibit) CGL-Driver Genes
Type: Antiapoptotic Oncogene
The proteins of BCL-2 family are classified into three subgroups, i.e., the anti-apoptotic/pro-survival proteins represented by BCL-2 and BCL-XL, the pro-apoptotic proteins represented by BAX and Bak, and the pro-apoptotic BH3-only proteins represented by BAD and BID.
Since the expression of Bcl-2 protein in tumor cells is much higher than that in normal cells, inhibitors targeting it have little effect on normal cells.
Scientific Papers found: Click to Expand⟱
6451- SAO,    α-Santalol functionalized chitosan nanoparticles as efficient inhibitors of polo-like kinase in triple negative breast cancer
- vitro+vivo, BC, MDA-MB-231
TumCP↓, selectivity↑, Bcl-2↓, PLK1↓, BAD↑, Casp↑, BAX↑, Dose↝, TumCG↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

PLK1↓, 1,  

Cell Death ⓘ

BAD↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Migration ⓘ

TumCP↓, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,   selectivity↑, 1,  
Total Targets: 9

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Bcl-2, B-cell CLL/lymphoma 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:407  Target#:27  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page